These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34895443)

  • 1. The association of new-onset diabetes mellitus and medical therapy for benign prostatic hyperplasia: A population-based study.
    Johnstone J; Lusty A; Tohidi M; Whitehead M; Tranmer J; Nickel JC; Siemens DR
    Can Urol Assoc J; 2021 Aug; 15(8):240-246. PubMed ID: 34895443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term risk of benign prostatic hyperplasia-related surgery and acute urinary retention in men treated with 5-alpha reductase inhibitor versus alpha-blocker monotherapy in routine clinical care.
    Bengtsen MB; Heide-Jørgensen U; Borre M; Nørgaard M
    Prostate; 2023 Jul; 83(10):980-989. PubMed ID: 37057816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Incident Antidepressant-Treated Depression Associated with Use of 5α-Reductase Inhibitors Compared with Use of α-Blockers in Men with Benign Prostatic Hyperplasia: A Population-Based Study Using the Clinical Practice Research Datalink.
    Hagberg KW; Divan HA; Nickel JC; Jick SS
    Pharmacotherapy; 2017 May; 37(5):517-527. PubMed ID: 28295443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
    Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
    Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
    Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
    BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
    Cindolo L; Pirozzi L; Sountoulides P; Fanizza C; Romero M; Castellan P; Antonelli A; Simeone C; Tubaro A; de Nunzio C; Schips L
    BMC Urol; 2015 Sep; 15():96. PubMed ID: 26391357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
    Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
    BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac Failure Associated with Medical Therapy of Benign Prostatic Hyperplasia: A Population Based Study.
    Lusty A; Siemens DR; Tohidi M; Whitehead M; Tranmer J; Nickel JC
    J Urol; 2021 May; 205(5):1430-1437. PubMed ID: 33616451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
    Morlock R; Goodwin B; Gomez Rey G; Eaddy M
    Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and economic impact of early versus delayed 5-alpha reductase inhibitor therapy in men taking alpha blockers for symptomatic benign prostatic hyperplasia.
    Kruep EJ; Hogue SL; Eaddy MT; Chandra MD
    P T; 2011 Aug; 36(8):493-507. PubMed ID: 21935297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
    Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
    BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?
    Fusco F; Arcaniolo D; Creta M; Piccinocchi G; Arpino G; Laringe M; Piccinocchi R; Longo N; Verze P; Mangiapia F; Imperatore V; Mirone V
    World J Urol; 2015 May; 33(5):685-9. PubMed ID: 25491675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data.
    Del Giudice F; Belladelli F; Glover F; Basran S; Li S; Mulloy E; Pradere B; Soria F; Krajewski W; Nair R; Muncey W; Seranio N; Eisenberg ML
    World J Urol; 2023 Oct; 41(10):2783-2791. PubMed ID: 37548746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Treated with Finasteride and Alpha Blocker Combination Therapy Versus Alpha Blocker Monotherapy in China: An Analysis of Electronic Medical Record Data.
    Fu Y; Han S; Wang L; Gao W; Wu E; Cao X; Wang J
    Adv Ther; 2018 Aug; 35(8):1191-1198. PubMed ID: 30014350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperthyroidism is not a significant risk of benign prostatic hyperplasia: A nationwide population-based study.
    Man KM; Chen KB; Chen HY; Chiang JH; Su YC; Man SS; Xie DD; Wang Y; Zhang ZQ; Bi LK; Zhang T; Yu DX; Chen WC
    Medicine (Baltimore); 2018 Sep; 97(39):e12459. PubMed ID: 30278528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer.
    Robinson D; Garmo H; Holmberg L; Stattin P
    Cancer Causes Control; 2015 Sep; 26(9):1289-97. PubMed ID: 26109464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suicide and Intentional Self-harm Among Older Men Treated With 5-Alpha Reductase Inhibitor or Alpha-blockers for Benign Prostatic Hyperplasia.
    Pennap D; Mosholder AD; Ajao A; Boley E; Dharmarajan S; Akhtar S; Naik KB; Flowers N; Wernecke M; MaCurdy TE; Kelman JA; Graham DJ
    Urology; 2024 Jun; ():. PubMed ID: 38880345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery.
    Souverein PC; Erkens JA; de la Rosette JJ; Leufkens HG; Herings RM
    Eur Urol; 2003 May; 43(5):528-34. PubMed ID: 12705998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis.
    Favilla V; Russo GI; Privitera S; Castelli T; Giardina R; Calogero AE; Condorelli RA; La Vignera S; Cimino S; Morgia G
    Aging Male; 2016 Sep; 19(3):175-181. PubMed ID: 27310433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.